Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Free Cash Flow (2016 - 2025)

Kiora Pharmaceuticals (KPRX) has disclosed Free Cash Flow for 11 consecutive years, with -$1.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Free Cash Flow fell 238.42% year-over-year to -$1.3 million, compared with a TTM value of -$10.0 million through Sep 2025, down 221.36%, and an annual FY2024 reading of $8.6 million, up 189.49% over the prior year.
  • Free Cash Flow was -$1.3 million for Q3 2025 at Kiora Pharmaceuticals, up from -$3.8 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $13.6 million in Q1 2024 and bottomed at -$3.8 million in Q2 2025.
  • Average Free Cash Flow over 5 years is -$1.4 million, with a median of -$2.6 million recorded in 2021.
  • The sharpest move saw Free Cash Flow skyrocketed 543.87% in 2024, then plummeted 238.42% in 2025.
  • Year by year, Free Cash Flow stood at -$2.9 million in 2021, then grew by 2.99% to -$2.8 million in 2022, then increased by 8.86% to -$2.6 million in 2023, then grew by 14.49% to -$2.2 million in 2024, then soared by 42.3% to -$1.3 million in 2025.
  • Business Quant data shows Free Cash Flow for KPRX at -$1.3 million in Q3 2025, -$3.8 million in Q2 2025, and -$2.7 million in Q1 2025.